Kornimate/medical-research-clean huggingface dataset:
rare kidney stone consortium patient registry

Conditions: Primary Hyperoxaluria; Dent Disease; Cystinuria; APRT Deficiency

Summary: the purpose of this study is to collect medical information from a large number of patients in many areas of the world with primary hyperoxaluria (ph), dent disease, cystinuria and aprt deficiency. this information will create a registry that will help us to compare similarities and differences in patients and their symptoms. the more patients we are able to enter into the registry, the more we will be able to understand the primary hyperoxalurias,dent disease, cystinuria and aprt and learn better ways of caring for patients with these diseases.

this study involves the collection of medical information to create a computer database or registry for patients with ph, dent disease, cystinuria and aprt deficiency. the information will be entered into the registry by your physician or health care provider. the computer web site for the registry is secure and protected by a required password. some information which will be entered may include your age at first symptoms of ph,dent disease, cystinuria or aprt, laboratory values, kidney function and the progress of your health over time. information for an individual patient can only be viewed by the appropriate physician or staff. once the information is entered into the registry, you will only be identified by a code number.

Eligibility criteria:
inclusion criteria: * individuals must have a definitive diagnosis of primary hyperoxaluria, dent disease, cystinuria or aprt deficiency. * individuals have a family history of a sibling with primary hyperoxaluria,dent disease, cystinuria or aprt deficiency. exclusion criteria: * individuals who do not have primary hyperoxaluria, dent disease, cystinuria or aprt deficiency.

Keywords: ph ph1 ph2 ph3 phi phii phiii ph noni-nonii primary hyperoxaluria primary oxalosis hyperoxaluria oxalate cystinuria cystine aprt adenine phosphoribosyl transferase deficiency dent disease dent
effect of nutriose supplementation on satiety, weight loss and adiposity in overweight subjects

Conditions: Overweight

Summary: nutriose is a food ingredient defined as a carbohydrate polymer of vegetable origin (wheat starch or corn) with a degree of polymerization ≥ 3 and chemically transformed. it is soluble in aqueous solution, very poorly digested in the small intestine, it mostly reaches the colon where it stimulates fermentation. afssa, in its opinion of july 30, 2007, considers that this ingredient is a "soluble dietary fiber." recent work in china in overweight volunteers have shown an effect of nutriose on satiation and satiety, and demonstrate an effect on reducing weight and fat mass. by its action on satiety and reduced food intake, the nutriose be of interest in the management of overweight or obese. among the possible mechanisms of action, are the metabolites produced by colonic fermentation of nutriose. the goal of this biomedical research is to study the effect of a dose of 14g/day of nutriose fb06 for 12 weeks on the evolution of weight, percentage of body fat and digestive tolerance in caucasians overweight subjects. to gather evidence to support mechanisms of action, it is proposed to measure before consumption, then every 4 weeks, the effects of nutriose fb06 on satiety and satiation and changes in colonic flora and its metabolites.


Eligibility criteria:
inclusion criteria: * healthy people * aged between 20 and 50 years * bmi between 27 and 29 kg/m2 * without metabolic syndrome * no pregnant nor nursing women * covered by social security * negative serology for hepatitis b/c and hiv * who signed the informed consent form exclusion criteria: * persons abusing drugs (laxatives, anti-diarrheal, agents acting on satiety) * person who doesn't want to stop taking food supplements containing pre- or probiotics during time of the study * person intolerant to gluten and / or allergic to wheat flour * person in diet during the last 3 months * person in vegetarian or vegan diet * person who donated blood during the 3 months preceding the study * inclusion in another clinical study * subjects receiving over 4,500 euros in the last 12 months (including the present study) * subjects presenting risk of non-compliance in the opinion of the recruiting doctor.

Keywords: overweight satiety functional food food intake digestive tolerance
a study to evaluate efficacy and safety of tez/iva in subjects aged 6 through 11 years with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this study will evaluate the efficacy of tezacaftor in combination with ivacaftor (tez/iva) in participants with cystic fibrosis (cf) aged 6 through 11 years, who are homozygous for the f508del mutation (f/f) or heterozygous for f508del with an eligible residual function mutation (f/rf).


Eligibility criteria:
key inclusion criteria: * homozygous for f508del or heterozygous for f508del and an rf mutation (as defined in the protocol). * participants with ppfev1 of ≥70 percentage points adjusted for age, sex, height. * participants with a screening lci2.5 result ≥7.5. * participants who are able to swallow tablets. key exclusion criteria: * clinically significant cirrhosis with or without portal hypertension. * colonization with organisms associated with a more rapid decline in pulmonary status. * solid organ or hematological transplantation. other protocol defined inclusion/exclusion criteria may apply.
establishment of a non-invasive and indirect measure of volitional pimax

Conditions: Neuromuscular Diseases; Respiratory Failure

Summary: respiratory failure is the main death cause in muscular diseases. non-invasive and volitional measures of inspiratory muscles strength include the nasal pressure with an occluded nostril and the maximal inspiratory pressure (pimax).unfortunately, volitional maneuvers depend of patient effort. the mean of this reseach is to validate a non-invasive and non-volitional technique to evaluate diaphragm strength at muscular diseases patients.the methdology consist to compar pimax measure to nerves magnetical stimulation maneuvers measure.


Eligibility criteria:
inclusion criteria: * neuromuscular disease * pimax evaluation indication exclusion criteria: * pregnant women * usual contre-indications for nuclear magnetic resonance

Keywords: phrenic nerves magnetic stimulations
a study of trilaciclib combined with mfolfirinox in the treatment of patients with advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: to observe the incidence of chemotherapy-induced myelosuppression and the safety of trilaciclib combined with mfolfirinox in patients with advanced pancreatic cancer receiving first-line treatment.

this study was a single-arm, exploratory clinical study. patients with advanced pancreatic cancer were screened and enrolled according to the inclusion and exclusion criteria described in the study protocol. informed consent was signed after full communication. patients with advanced pancreatic cancer who received first-line treatment were treated with trilaciclib +mfolfirinox. the incidence of chemotherapy-induced myelosuppression was used as the primary endpoint to observe whether trilaciclib could reduce the occurrence or degree of chemotherapy-induced myelosuppression.

Eligibility criteria:
inclusion criteria: * age 18-75 years * ecog score 0 or 1 * expected survival≥12 weeks * patients with histologically or cytologically confirmed pancreatic cancer * have not received any antineoplastic therapy prior to treatment * major organ functions within 7 days prior to treatment shall meet the following criteria: a. neutrophil count ≥1.5×109 /l； b. hemoglobin ≥10g/dl； c. platelet count ≥100×109 /l * biochemical examination shall meet the following standards: a、total bilirubin(tbil)≤1.5times the upper limit of normal value(uln); b、alt and ast≤1.5×uln ; c、creatinine clearance(ccr)≥60ml/min * patients of reproductive age(including female and male patients'female companions)must use effective birth control measures * subjects voluntarily joined the study and signed an informed consent form(icf) * it is expected that the patient has good compliance and can follow up the efficacy and adverse reactions according to the protocol requirements exclusion criteria: * had received systemic antineoplastic therapy * pregnant and lactating women. women of childbearing age had to test a negative pregnancy test within 7 days before enrollment * substance abuse, clinical or psychological or social factors that may interfere with informed consent or the conduct of the study
transverse abdominal plane block vs. ilio-inguinal ilio-hypogastric block in pediatric inguinal surgery

Conditions: Analgesia; Ultrasound Guided Block

Summary: the ilio-inguinal ilio-hypogastric (iiih) nerve block remains the gold standard analgesic technique after inguinal surgery in children. transverse abdominal plane (tap) block has been reported to provide effective analgesia after lower abdominal surgery in adults. the aim of our study was to compare the analgesic effect of ultrasound-guided tap block to iiih nerve block after inguinal surgery in children.

the study aimed to compare the analgesic effect of ultrasound-guided transverse abdominal plane (tap) block to ilio-inguinal ilio-hypogastric (iiih) nerve block in children after inguinal surgery. this prospective, randomized study included children aged six months to twelve years, classified as asa i or ii, scheduled for elective unilateral inguinal surgery. participants received either a tap block or an iiih block with bupivacaine following standardized induction of general anesthesia. analgesics were not systematically administered post-induction. postoperative pain was monitored for six hours in the hospital, and if the cheops score exceeded 7, paracetamol was administered, with nalbuphine as a secondary option if needed. at home, parents assessed pain using the ppmp score, administering paracetamol and ibuprofen if necessary. primary outcomes included postoperative analgesia quality, determined by time to first analgesic requirement and the need for analgesics at hospital and home. secondary outcomes measured included block performance duration, parental satisfaction, and incidence of complications.

Eligibility criteria:
inclusion criteria: * children aged 6 months to 12 years * asa physical status 1 or 2 * scheduled for unilateral inguinal surgery exclusion criteria: * children scheduled for bilateral surgery or associated procedures (e.g., circumcision) * parental refusal

Keywords: transverse abdominal plane bloc pain analgesia ultrasound children
a prospective, single blinded study for predicting colon polyp histology with narrow band imaging

Conditions: Colonoscopy; Adenomatous Polyp; Neoplastic

Summary: the investigators hypothesize that nbi will have a high accuracy in predicting polyp histology real time during a colonoscopy by visualization of the surface mucosal and vascular patterns. aim#1: to determine the sensitivity, specificity and accuracy of nbi and standard white light colonoscopy for predicting polyp histology by evaluating the surface mucosal and vascular patterns during colonoscopy. aim#2: to determine the inter-observer agreement between investigators for the recognition of various polyp patterns.


Eligibility criteria:
inclusion criteria: * referral for screening or surveillance colonoscopy * the ability to provide informed consent exclusion criteria: * prior surgical resection of any portion of colon * prior history of colon cancer * history of inflammatory bowel disease * use of anti-platelet agents or anticoagulants that precludes removal of polyps during the procedure * poor general condition or any other reason to avoid prolonged procedure time * history of polyposis syndrome or hereditary non-polyposis colon cancer * inability to give informed consent

Keywords: narrow band imaging
human rabies immunoglobulin (hrig)- dosage determination and interference with the active immune response

Conditions: Rabies

Summary: dosage of rabies immune globulin was calculated from the victim's body weight, then the amount of rabies immune globulin would be injected as much as possible to all of the wounds. increase dosage of rabies immune globulin was needed in situation of multiple severe bite-wounds especially among children whose had lower body weight than adults. our study would be conducted in order to determine whether the increase dosage of rabies immune globulin would interfere with the protective antibody levels against rabies.

* controlled trial study. * all 50 volunteers who had never had rabies immunization would be enrolled and designated into 2 groups. group 1 : 15 healthy volunteers age 18 - 60 yr who were attacked by mammals, possible exposed to rabies and had who category iii exposure, all receive standard post - exposure rabies treatment with 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 20 iu/kg of human rabies immune globulin (hrig). group 2 : 35 healthy volunteers age 18 - 60 yr receive 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 40 iu/kg of human rabies immune globulin (hrig). 5 cc - blood would be drawn from all volunteers before vaccination and on day 14, 28 and 90 for rabies neutralizing antibody titers (rnab). the gmts of rnab among both groups would be analyzed and compared.

Eligibility criteria:
inclusion criteria: * healthy volunteers age 18-60 years. exclusion criteria: * received prior rabies immunization * pregnancy * immunocompromised conditions

Keywords: rabies immunoglobulin dosage
impact of ltbi treatment on glucose tolerance and chronic inflammation

Conditions: Latent Tuberculosis; Diabetes Mellitus, Type 2

Summary: this study will be investigating the effect of latent tuberculosis infection (ltbi) treatment on glucose tolerance and low-grade inflammation. almost a century ago, researchers proposed that diabetes (dm) was associated with increased risk of tuberculosis infection (tb). a more recent systematic review concluded that dm increases the relative risk for tb 3.1 times. reversely, tb may affect the glycaemic control; tb is in many cases a chronic infection characterised by long term low-grade inflammation and weight loss, and persons with tb are known to be at risk of hyperglycaemia and dm at time of diagnosis. a latent infection with the m.tuberculosis bacteria is "silent" without symptoms. 1,7 billion have ltbi on a global scale. event though the infected person does not experience symptoms, increased background inflammation has been shown in ltbi patients in previous studies. we also know that an increase in inflammatory markers precedes clinical development of dm, and that subclinical inflammation contributes to insulin resistance. we hypothesise that ltbi contributes to dysregulated glucose metabolism due to increased low-grade inflammation, and that treatment will reduce low-grade inflammation and improve glucose tolerance.


Eligibility criteria:
inclusion criteria: inclusion criteria for the ltbidm arm: * 18+ years * known dm type 2 inclusion criteria for ltbi arm * 18+ years * ltbi positive * no diagnosis with or known dm (1 and 2) exclusion criteria (both arms) : * previous treatment for tb or ltbi * pregnancy * type 1 dm * known immunosuppression such as: hiv, steroid treatment within 14 days before inclusion, daily nsaid treatment, ongoing chemotherapy, ongoing immunomodulating treatment or splenectomy * known contraindication to both study drugs * known active liver disease * known severe inflammatory or rheumatological diseases with immune activation and need for prolonged systemic treatment such as ibd, ra, psoriasis and wegners granulomatosis * recent antibiotic treatment (\>2 days) or severe infection within 14 days before enrollment * known active cancer

Keywords: low-grade inflammation glucose metabolism body composition cytokines adipokines biomarkers
a comparative study between 1mg and 3 mg of granisetron in the prevention of postoperative nausea and vomiting in strabismus ophthalmic surgeries during general anesthesia

Conditions: 1mg Vs 3 mg of Granisetron

Summary: investigators aim to determine the optimal dose of granisetron in strabismus ophthalmic surgeries under general anesthesia to prevent postoperative nausea and vomiting

postoperative nausea and vomiting (ponv) are common and distressing symptoms after surgery under general anesthesia. despite advances in balanced anesthesia in recent decades, ponv can result in delayed discharge from the post-anesthesia care unit (pacu) recovery room, unexpected hospitalization and increase in medical costs. the latest class of antiemetic for the prevention and treatment of ponv are the serotonin receptor antagonists (ondansetron, granisetron). these antiemetics do not have the negative effects of the older generations. headache and dizziness are the main adverse effects of the serotonin receptor antagonists in the dosages used for ponv . the fda approved dose for the prevention of ponv is 1mg. this is based on a dose range study from wilson and associates in which 0.1, 1.0, and 3.0 mg were associated with risk ratios for postoperative vomiting. the majority of studies on granisetron suggest that 3mg is superior to 1mg for the prevention of ponv, but those were published by a single center and there have been serious concerns about the validity of the data. in previous studies done on elective open abdominal surgery or vaginal hysterectomy but not in strabismus ophthalmic surgeries. the ocular surgery associated with the highest incidence of ponv is strabismus surgery up to 85%. vomiting after surgery is more likely 2-8hours than immediate postoperatively. strabismus is a day case procedure and thus participants have to cope with emesis in the recovery room, or when traveling, or at home. in this study, investigators compared two doses of granisetron in strabismus ophthalmic surgeries under general anesthesia

Eligibility criteria:
inclusion criteria: * • adult patients \> 18 years old. * asa i and ii. * patients scheduled for strabismus surgery. exclusion criteria: * • asa class \> ii. * patients with known hypersensitivity or contraindication to any of the study medications. * patients who had chronic nausea and vomiting or experienced retching, vomiting, moderate to severe nausea in the preoperative day. * patients who had received an antiemetic drug in the preoperative day. * patients with a body mass index ≥36. * pregnant or breast feeding female patient. * patients with gastrointestinal diseases. * patients with a history of motion sickness, diabetes mellitus, and git pathology (gastritis, hematemesis, peptic ulcer).
a multi-site, pre-clinical, prospective data collection study in patients undergoing a right heart catheterization

Conditions: Heart Failure

Summary: acorai is developing a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters in patients with suspected or confirmed heart failure, and/or pulmonary hypertension, who require hemodynamic assessment. the device will be intended as a companion test or clinical decision support tool to be used and interpreted by qualified healthcare professionals to aid standard-of-care clinical assessment in identifying hemodynamic congestion and supporting personalized treatment of heart failure and pulmonary congestion. this study is part of the development of a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters. it will be conducted to collect the data needed to train the machine learning models retrospectively.


Eligibility criteria:
inclusion criteria: * subject is at least 18 years of age at the time of screening. * subject is willing and physically able to comply with the specified evaluations as per the protocol. * subject is referred for invasive hemodynamic assessment with right heart catheterization. * subject has provided written informed consent using the approved consent form. exclusion criteria: * discretionary exclusion when the inclusion of a potential subject is not in their best interest or not in the interest of compliant performance of the study.
walking football as a supportive medicine for patients with prostate cancer

Conditions: Prostate Cancer; Androgen Deprivation Therapy

Summary: androgen deprivation therapy (adt) is widely used in men with prostate cancer (pca) to delay disease progression and enhance survival. the use of adt is often associated with a vast spectrum of side effects that considerably reduce quality of life. exercise has been proposed as a non-pharmacological strategy to counter some adverse effects of adt among patients with pca. particularly, recreational football-based interventions have been suggested as an enjoyment approach to involve patients with pca in regular exercise practice. given its intermittent nature and vigorous efforts, adverse events associated with recreational football practice have been reported. to handle this issue and to involve patients with pca in recreational football practice, walking football has emerged as a more suitable exercise modality

this study was design as a randomized controlled trial, with two study arms, which aims to analyse the feasibility, safety of a supervised walking football program in patients with pca. moreover, the effects on health-related quality of life; bone mineral density; body composition; physical fitness; physical activity levels; inflammatory and metabolic profile; cognitive function; and cost-effectiveness will be complementarily analysed. recruitment will be conducted by invitation of centro hospitalar de vila nova de gaia/espinho (chvng/e; vila nova de gaia, portugal, e.p.e) oncologists and urologists. patients who agree to participate in this study will be referred to a study coordinator (medical oncologist) and will be randomly allocated (1:1 ratio) to one of the two study-arms. in addition to standard pca care, patients in the interventional group (ig) will perform 3 times per week a supervised walking football program over 16 weeks and plus 16 additional weeks. patients allocated to control group (cg) will receive standard pca medical care and will be instructed to maintain daily-life routines. after the first 16 weeks, the control group patients' will be invited to join and preform the exercise intervention (additional 16 weeks). walking football exercise sessions will be conducted on an indoor sports hall, supervised by one exercise physiologist and a football coach. exercise intensity will be monitored through heart rate and rated perceived exertion.

Eligibility criteria:
inclusion criteria: * patients diagnosed with pca * under castration therapy for more than 3 months * planned to be under castration for more than 6 months * follow-up at the medical oncology department and/or urology department of the hospital center vila nova de gaia/espinho. exclusion criteria: * medical or surgical contraindications for exercise. * t-score \< -2.5

Keywords: prostate cancer androgen deprivation therapy walking football
proof of concept of an anaplerotic study using brain phosphorus magnetic resonance spectroscopy in huntington disease

Conditions: Huntington Disease

Summary: the purpose of this project is to study the efficacy of an anaplerotic treatment on brain energy profile evolution at an early stage of the huntington disease.


Eligibility criteria:
inclusion criteria: * 5 \< uhdrs \< 50 * age \> 18 years * ability to undergo mr scanning * covered by french social security exclusion criteria: * evidence of psychiatric disorder * attendant neurological disorder * contraindications to mri (claustrophobia, metallic or material implants) * severe head injury * unable to understand the protocol * pregnancy * failure to give informed consent * subjects with exclusion criteria required by french law (e.g. subjects who require a legally authorized representative to obtain consent) * unwillingness to be informed in case of abnormal mri